List view / Grid view
CRISPR is a tool used by researchers to precisely edit genes and has shown potential for treating genetic diseases. This article delves into some recent developments and explores what the future holds for CRISPR.
Researchers have discovered a potential new strategy for treating myelodysplastic syndrome, which has shown to be successful in pre-clinical trials.
A novel CDK8 inhibitor has been developed by scientists at Ryvu Therapeutics. Dr Krzysztof Brzozka showcases this molecule and explains the R&D behind it.
A study that identified 12 novel compounds that may prove valuable against new drug targets for leishmaniasis and Chagas disease was not without complication. Here, we discuss the findings but also the challenges the researchers reported in their hit-to-lead study.
A new process for identifying and biosynthesising drug candidates has been discovered by researchers at the Carl R Woese Institute for Genomic Biology.
Monoclonal antibodies have shown great promise in the treatment of various cancers. This article discusses how therapeutic antibodies are produced and the various treatment strategies that are currently being adopted.
The systematic successful treatment of cancer still eludes us and in an effort to refine this area of targeted medicine, Lauri Paasonen and colleagues explore the potential of using patient-derived cells (PDCs) for devising a personalised treatment strategy for solid tumours.
Currently, there is no licensed treatment to slow or stop the progression of Parkinson’s disease. However, a team at Sheffield University in the UK are currently working to identify compounds that target the dopaminergic brain cells affected by the disease. Nikki Withers speaks to Dr Heather Mortiboys to hear how…
Aparajita Dubey summarises the recent trends in upstream bioprocessing and highlights the challenges and solutions involved in its process development.
Upstream bioprocessing is the epicentre of biologics development, wherein scientists piece together a series of carefully chosen processes with contributing components and parameters to enable the production of highly effective biotherapeutics. Unjulie Bhanot explains why an effective data management system is vital in this quest for the next big therapeutic.
Marc Baiget-Francesch highlights interesting developments in the field of protein drug design and explains how continual software improvements are speeding up the process.
Vernalis Research is based at Granta Park in Cambridge, UK and specialises in the development and application of fragment- and structure-based drug discovery methods. Nikki Withers met with Vernalis’ Research Director, James Murray, to discuss the company’s innovative approach to target discovery and how they sustain symbiotic collaborations to progress…
CRISPR is the buzzword of the moment in the drug discovery industry – mainly due to its potential to correct disease-causing mutations. However, those using the technology need to be mindful that it is used responsibly, and possible risks are considered before use. Mark Behlke discusses the potential of CRISPR…
Steven van Helden, Chief Technology Officer at Pivot Park Screening Centre (PPSC), relies on efficient microplate readers for effective hit discovery.
We are on the precipice of realising the true potential of genomics studies. Following completion of the Human Genome Project six years ago, huge strides have been made in understanding how the genome works, shedding light on disease pathogenesis and forging therapeutic efforts. In this article, Pushpanathan Muthuirulan explains how…
